PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 9:44 AM ET

Sponsor Check › Issuer

L

LAUNCHCYTE LLC

Limited Liability Company · organized in Pennsylvania · formed more than five years before filing · Pittsburgh, PA

$1.05Mreported sold (max)
11investors (max)
5offerings
10Form D filings
2009–2014filing years
0new, last 12 mo
Follow this issuerConnect me with this sponsorEmail me the full reportLook further ↓

Data last updated Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer Jan 28, 2014 · Courts (RECAP) last checked: Oct 24, 2026, 2:11 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

LAUNCHCYTE LLC is a limited liability company organized in Pennsylvania (formed more than five years before filing), based in Pittsburgh, PA.

What this means A deal company is usually set up for one investment; its Form D is the notice it files after selling to investors.

It has filed 10 Form D filings (6 originals, 4 amendments) for 5 offerings between May 2009 and Jan 2014. The latest filing of each offering reports a combined $2.48M sold of $5.08M offered to 25 investors; industry as reported: biotechnology; latest exemption Rule 506(b).

What this means A repeat filer — 5 separate raises over about 5 years. Amendments are routine updates (an ongoing raise must update its Form D at least once a year).

Key people as listed: Adam W. Verost (director), Barbara A. Carryer (director), Gregory T. Hebrank (director), Michael A. Turpin (director), Robert Unkovic (director) and 6 more.

What this means These are the people the company itself named as running or promoting it. Tap a name to see every other deal they are on.

No sales commissions, finder's fees or proceeds to insiders are reported. No sales-compensation recipients are listed.

What this means No broker was paid — the sponsor sold it directly to investors.

Activity: 0 new offerings in the last 12 months; latest amendment Oct 12, 2010; latest filing Jan 28, 2014.

What this means No new raise filed in the past year — this deal company may be done raising, or simply quiet.

Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched LAUNCHCYTE LLC.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY), property records (NYC, FL, IL and TX counties) — none found.

What this means Nothing turned up where we looked (4 sources). That does not prove there is nothing — it means none was found in those sources on that date.

We compared 10 public filings for LAUNCHCYTE LLC and found 15 differences, 1 worth asking the sponsor about: Amount sold went down between filings; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

Business registration (state registry / Secretary of State)

State business registry (Secretary of State) 0 records matched to LAUNCHCYTE LLC

No Secretary of State record matched in the registries searched (including PA, the state of incorporation the issuer reports). Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).

What the community is saying

Community search for LAUNCHCYTE LLC has not run yet — it is joining a line of 39,677 names; searches run around the clock at the hosts' allowed rate. Searched so far: 641 names.

Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:11 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched LAUNCHCYTE LLC..

State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).

3. Bankruptcies

None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:11 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

No comparisons published

What is compared

No public statement by this issuer has been collected yet, so there is nothing to compare. Sources compared: the sponsor's own website (known from the issuer's own filings — Form C issuer website, EDGAR company profile — an approved profile claim or Form ADV Item 1.I of its matched adviser) · SEC Form D · SEC Form ADV (IAPD) · Internet Archive · No website is on file for this issuer yet.

15 differences found between the filings for LAUNCHCYTE LLC — 1 worth asking about (compared 10 filings on Oct 24, 2026)

Worth asking · Jan 6, 2010

Amount sold went down between filings — LAUNCHCYTE LLC

The Jan 6, 2010 filing says $1,021,293 sold; the Jan 6, 2010 Form D/A says $776,720 sold — $244,573 less.

What this means Amounts sold normally only go up as a raise continues. A drop can mean investors were refunded, a figure was corrected, or an earlier number was wrong. Ask the sponsor which it was.

Form D/A (earlier) · Jan 6, 2010 ↗Form D/A (later) · Jan 6, 2010 ↗LAUNCHCYTE LLC — PartnerFacts page ↗
Sources
Note · Jan 28, 2014

14 other issuers file from the same address — LAUNCHCYTE LLC

The address on file, 2403 Sidney St, Ste 270, Pittsburgh, PA, is used by 14 issuers in our index across 3 sponsor groups; 14 are outside this issuer's group. It is on our registered-agent / shared-office list (14 issuers in 9 unrelated clusters).

What this means Many unrelated companies file from this address. Often a registered agent or a fund administrator; sometimes a shared office. Ask where the team actually works.

LAUNCHCYTE LLC — PartnerFacts page ↗EDGAR filer page · LAUNCHCYTE LLC ↗
Sources
Note · May 19, 2011 – Jun 2, 2011

No amendment in the last 12 months on an offering that may still be open — LAUNCHCYTE LLC (latest filing Jun 2, 2011)

The latest filing for this offering is dated Jun 2, 2011 (first sale May 19, 2011). It reports $1,055,000 sold of $1,575,000 offered. No later amendment is in our index as of Oct 24, 2026.

What this means SEC rules expect a yearly amendment while an offering is still going. The raise may simply have ended — a Form D does not say when it closed. Ask the sponsor whether the offering closed, when, and at what amount.

Form D · Jun 2, 2011 ↗LAUNCHCYTE LLC — PartnerFacts page ↗
Sources
Note · Sep 20, 2010 – Oct 12, 2010

No amendment in the last 12 months on an offering that may still be open — LAUNCHCYTE LLC (latest filing Oct 12, 2010)

The latest filing for this offering is dated Oct 12, 2010 (first sale Sep 20, 2010). It reports $493,697 sold of $607,341 offered. No later amendment is in our index as of Oct 24, 2026.

What this means SEC rules expect a yearly amendment while an offering is still going. The raise may simply have ended — a Form D does not say when it closed. Ask the sponsor whether the offering closed, when, and at what amount.

Form D/A · Oct 12, 2010 ↗LAUNCHCYTE LLC — PartnerFacts page ↗
Sources
Note · Dec 18, 2009 – Jun 15, 2010

No amendment in the last 12 months on an offering that may still be open — LAUNCHCYTE LLC (latest filing Jun 15, 2010)

The latest filing for this offering is dated Jun 15, 2010 (first sale Dec 18, 2009). It reports $926,720 sold of $1,150,000 offered. No later amendment is in our index as of Oct 24, 2026.

What this means SEC rules expect a yearly amendment while an offering is still going. The raise may simply have ended — a Form D does not say when it closed. Ask the sponsor whether the offering closed, when, and at what amount.

Form D/A · Jun 15, 2010 ↗LAUNCHCYTE LLC — PartnerFacts page ↗
Sources
Note · Dec 31, 2009 – Jan 6, 2010

Offering amount changed between filings — LAUNCHCYTE LLC

The Dec 31, 2009 filing says $229,720 offered; the Jan 6, 2010 Form D/A says $1,021,293.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · Dec 31, 2009 ↗Form D/A (later) · Jan 6, 2010 ↗LAUNCHCYTE LLC — PartnerFacts page ↗
Sources
Note · Jan 6, 2010

Offering amount changed between filings — LAUNCHCYTE LLC

The Jan 6, 2010 filing says $1,021,293 offered; the Jan 6, 2010 Form D/A says $1,150,000.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D/A (earlier) · Jan 6, 2010 ↗Form D/A (later) · Jan 6, 2010 ↗LAUNCHCYTE LLC — PartnerFacts page ↗
Sources
Note · May 28, 2009 – Dec 31, 2009

Offering amount lowered between filings — LAUNCHCYTE LLC

The May 28, 2009 filing says $1,150,000 offered; the Dec 31, 2009 Form D says $229,720.

What this means The target raise got smaller. That can mean the plan shrank or the sponsor stopped early. Ask what changed in the deal.

Form D (earlier) · May 28, 2009 ↗Form D (later) · Dec 31, 2009 ↗LAUNCHCYTE LLC — PartnerFacts page ↗
Sources
Note · Dec 31, 2009 – Jan 6, 2010

Minimum investment changed between filings — LAUNCHCYTE LLC

The Dec 31, 2009 filing lists a minimum of $75,000; the Jan 6, 2010 Form D/A lists $333,436.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · Dec 31, 2009 ↗Form D/A (later) · Jan 6, 2010 ↗LAUNCHCYTE LLC — PartnerFacts page ↗
Sources
Note · Jan 6, 2010

Minimum investment changed between filings — LAUNCHCYTE LLC

The Jan 6, 2010 filing lists a minimum of $333,436; the Jan 6, 2010 Form D/A lists $0.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D/A (earlier) · Jan 6, 2010 ↗Form D/A (later) · Jan 6, 2010 ↗LAUNCHCYTE LLC — PartnerFacts page ↗
Sources
Note · May 28, 2009 – Dec 31, 2009

Minimum investment changed between filings — LAUNCHCYTE LLC

The May 28, 2009 filing lists a minimum of $0; the Dec 31, 2009 Form D lists $75,000.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · May 28, 2009 ↗Form D (later) · Dec 31, 2009 ↗LAUNCHCYTE LLC — PartnerFacts page ↗
Sources
Note · May 28, 2009 – Jan 28, 2014

Michael Turpin is written 2 different ways on the filings

listed as "Michael Turpin" on 9 filings (from May 28, 2009), and "Michael A. Turpin" on the Jan 28, 2014 filing.

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · May 28, 2009 ↗Form D · Jan 28, 2014 ↗Michael Turpin — PartnerFacts page ↗
Sources
Note · Apr 24, 2012 – Jan 28, 2014

Adam W. Verost is written 2 different ways on the filings

listed as "Adam Verost" on the Apr 24, 2012 filing, and "Adam W. Verost" on the Jan 28, 2014 filing.

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Apr 24, 2012 ↗Form D · Jan 28, 2014 ↗Adam W. Verost — PartnerFacts page ↗
Sources
Note · May 28, 2009 – Dec 31, 2009

Gregory T. Hebrank is written 2 different ways on the filings

listed as "Gregory T. Hebrank" on 8 filings (from May 28, 2009), and "Gregory Hebrank" on 2 filings (from Dec 31, 2009).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · May 28, 2009 ↗Form D · Dec 31, 2009 ↗Gregory T. Hebrank — PartnerFacts page ↗
Sources
Note · Jan 28, 2014

Address on file is a registered agent / shared office — LAUNCHCYTE LLC

The latest filing lists 2403 Sidney St, Ste 270, Pittsburgh, PA. That address is used by 14 issuers in our index (14 issuers in 9 unrelated clusters).

What this means Many small companies use a registered agent's address — it is legal and common. It means the Form D address is not where the team works. Ask where the business operates and who runs it day to day.

Form D · Jan 28, 2014 ↗LAUNCHCYTE LLC — PartnerFacts page ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

None reported on 5 offerings — no sales commissions, finder's fees or proceeds to insiders

Per-offering detail
Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Jan 28, 2014 D
File 021-210797
$0$0$0None listed on this filingEDGAR ↗
Apr 24, 2012 D
File 021-177127
$0$0$0None listed on this filingEDGAR ↗
Jun 2, 2011 D
File 021-160653
$0$0$0None listed on this filingEDGAR ↗
Oct 12, 2010 D/A
File 021-148367
$0$0$0None listed on this filingEDGAR ↗
Jun 15, 2010 D/A
File 021-39199
$0$0$0None listed on this filingEDGAR ↗

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Property records 0 documents · 0 ownership records · last checked Oct 24, 2026, 9:34 AM ET · NYC and Cook County lookup still to run

0 recorded documents and 0 ownership records matched to LAUNCHCYTE LLC in the sources searched.

Not found in sources searched as of Oct 24, 2026, 9:34 AM ET: Hillsborough County FL Clerk of Court Official Records daily index (publicrec.hillsclerk.com D/P/M files), 2 daily files (Oct 14, 2026 to Oct 15, 2026) — loaded Oct 23, 2026, 8:59 PM ET; Harris County TX (HCAD ownership rolls 2005–2026) — 1,032,426 records, loaded Oct 24, 2026, 8:00 AM ET; Dallas County TX (DCAD ownership rolls 2021–2027) — 285,535 records, loaded Oct 24, 2026, 8:20 AM ET; Hillsborough County FL (FL DOR 2026 ownership roll + Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026), Miami-Dade County FL (FL DOR 2026 ownership roll), Broward County FL (FL DOR 2026 ownership roll), Palm Beach County FL (FL DOR 2026 ownership roll) — 514,336 records, loaded Oct 24, 2026, 8:25 AM ET; King County WA (Assessor sale records 0000-00-00–2026-10-14; no owner-of-record names published) — 538,619 records, loaded Oct 24, 2026, 8:27 AM ET; Cook County IL (Assessor sale records 1982–2026 + ownership rolls 2014–2026) — 1,031,843 records, loaded Oct 24, 2026, 9:05 AM ET. Still to be looked up for this issuer: NYC ACRIS via NYC Open Data (Real Property Parties 636b-3b5g, Master bnx9-e6tj, Legals 8h5j-fqxa, Document Control Codes 7isb-wh4c) · NYC PLUTO ownership via NYC Open Data (64uk-42ks) · Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp). Records in other counties, and recorder indexes we do not yet cover, were not searched.

Property records coverage: New York City (ACRIS recorded documents and PLUTO ownership, looked up per issuer when its page is viewed; re-checked when the page is viewed again more than 30 days after the last check); Harris County TX (ownership only, no deed, mortgage or sale records; HCAD ownership rolls 2005–2026); Dallas County TX (ownership only, no deed, mortgage or sale records; DCAD ownership rolls 2021–2027); Hillsborough County FL (FL DOR 2026 ownership roll + Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026), Miami-Dade County FL (FL DOR 2026 ownership roll), Broward County FL (FL DOR 2026 ownership roll), Palm Beach County FL (FL DOR 2026 ownership roll); King County WA (Assessor sale records 0000-00-00–2026-10-14; no owner-of-record names published); Cook County IL (Assessor sale records 1982–2026 + ownership rolls 2014–2026); also looked up per issuer when its page is viewed. Recorder indexes (party names on deeds, mortgages and liens) in TX, AZ, NV, CA and WA counties and outside the Clerk index in FL, mortgages and liens outside NYC and Hillsborough County, lis pendens and foreclosure notices everywhere, Los Angeles County CA, Clark County NV, New York City bulk pass (not finished; per-issuer lookups only so far), Maricopa County AZ (loader ready; commercial-purpose statement not yet filed), Salt Lake County UT, and all other counties are not covered — not searched. Last refresh by source: Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp) Oct 24, 2026, 9:05 AM ET; Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp) Oct 24, 2026, 8:30 AM ET; King County WA Assessor Real Property Sales extract (EXTR_RPSale.csv) Oct 24, 2026, 8:27 AM ET; Florida DOR NAL roll (Palm Beach 60) Oct 24, 2026, 8:25 AM ET; Florida DOR NAL roll (Broward 16) Oct 24, 2026, 8:24 AM ET; Florida DOR NAL roll (Dade 23) Oct 24, 2026, 8:23 AM ET; Florida DOR NAL roll (Hillsborough 39) Oct 24, 2026, 8:21 AM ET; Dallas Central Appraisal District ACCOUNT_INFO.CSV Oct 24, 2026, 8:20 AM ET; Harris County Appraisal District real_acct.txt Oct 24, 2026, 8:00 AM ET; Hillsborough County FL Clerk daily index Oct 23, 2026, 8:59 PM ET. NYC and Cook County are also looked up per issuer when its page is viewed; the most recent such lookup on this site finished Oct 24, 2026, 3:30 AM ET. Parties are named as the recorder's index names them (role suffixes as recorded); no address, account number or trust date is shown for an individual, and individual owners of record (home ownership) are not matched or shown. Items still in human review are not shown.

Offerings (SEC Form D)

Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.

Offerings at a glance — 5 offerings, 10 filings (one row per SEC file number)
File no.Original Form DLatest filingAmendmentsOffered (latest)Sold (latest)Industry (latest)
021-210797Jan 28, 2014 EDGAR ↗Jan 28, 2014 D EDGAR ↗0$1,000,000$0Biotechnology
021-177127Apr 24, 2012 EDGAR ↗Apr 24, 2012 D EDGAR ↗0$750,000$0Biotechnology
021-160653Jun 2, 2011 EDGAR ↗Jun 2, 2011 D EDGAR ↗0$1,575,000$1,055,000Biotechnology
021-148367Sep 30, 2010 EDGAR ↗Oct 12, 2010 D/A EDGAR ↗1
latest Oct 12, 2010
$607,341$493,697Biotechnology
021-39199May 28, 2009 EDGAR ↗Jun 15, 2010 D/A EDGAR ↗3
latest Jun 15, 2010
$1,150,000$926,720Biotechnology

Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.

Jan 28, 2014 D Biotechnology — $0 sold of $1,000,000 · 0 investors EDGAR ↗
FilingForm D filed Jan 28, 2014
SEC file no. 021-210797 · accession 0000898432-14-000076
Raise progress$0 sold of $1,000,000 offered (0%) · $1,000,000 remaining
Issuer's note: Offering amount includes the exercise price of the Warrants
Filing timingDate of first sale: Yet to occur · Form D filed: Jan 28, 2014
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors0 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$10,000
Securities offeredDebt; Option, warrant or other right to acquire; Security to be acquired upon exercise
Entity detailsOrganized in PENNSYLVANIA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byThomas Petzinger Jr., CEO (Jan 28, 2014)
Market contextMinimum investment: $10,000. Typical range for similar offerings: $10,000–$50,000.
Offering size: $1,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 0. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Apr 24, 2012 D Biotechnology — $0 sold of $750,000 · 0 investors EDGAR ↗
FilingForm D filed Apr 24, 2012
SEC file no. 021-177127 · accession 0000898432-12-000520
Raise progress$0 sold of $750,000 offered (0%) · $750,000 remaining
Filing timingDate of first sale: Yet to occur · Form D filed: Apr 24, 2012
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors0 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$0 as filed (no minimum reported)
Securities offeredEquity
Entity detailsOrganized in PENNSYLVANIA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byThomas Petzinger Jr., CEO (Apr 24, 2012)
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Jun 2, 2011 D Biotechnology — $1,055,000 sold of $1,575,000 · 6 investors EDGAR ↗
FilingForm D filed Jun 2, 2011
SEC file no. 021-160653 · accession 0001125594-11-000001
Raise progress$1,055,000 sold of $1,575,000 offered (67%) · $520,000 remaining · first sale May 19, 2011
Filing timingDate of first sale: May 19, 2011 · Form D filed: Jun 2, 2011 (14 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale5,638 days (15.4 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors6 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$0 as filed (no minimum reported)
Securities offeredEquity
Entity detailsOrganized in PENNSYLVANIA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byThomas Petzinger Jr., CEO (Jun 2, 2011)
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Oct 12, 2010 D/A Biotechnology — $493,697 sold of $607,341 · 8 investors EDGAR ↗
FilingForm D/A (amendment) filed Oct 12, 2010 · amends 0001125594-10-000004 ↗
SEC file no. 021-148367 · accession 0001125594-10-000005 · filing 2 of 2 in this offering
Raise progress$493,697 sold of $607,341 offered (81%) · $113,644 remaining · first sale Sep 20, 2010
Issuer's note: Total offering amount includes interest on convertible promissory notes through October 29, 2010, which is the anticipated outside date for closing. Interest continues to accrue on notes until converted at closing.
Filing timingDate of first sale: Sep 20, 2010 · Original Form D filed: Sep 30, 2010 (10 days after first sale) · This amendment (Form D/A) filed: Oct 12, 2010
This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn.
Time since first sale5,879 days (16.1 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. This filing is an amendment dated Oct 12, 2010. Most recent amendment for this offering in our index: this filing, Oct 12, 2010.
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors8 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$0 as filed (no minimum reported)
Securities offeredEquity
Entity detailsOrganized in PENNSYLVANIA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byThomas Petzinger Jr., CEO (Oct 12, 2010)
Changes vs previous filing
  • total sold: $379,026 (Sep 30, 2010) → $493,697 (Oct 12, 2010)
  • remaining: $228,315 (Sep 30, 2010) → $113,644 (Oct 12, 2010)
  • investors: 7 (Sep 30, 2010) → 8 (Oct 12, 2010)
Compared with the D filed Sep 30, 2010 (EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn.
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Sep 30, 2010 D Biotechnology — $379,026 sold of $607,341 · 7 investors EDGAR ↗
FilingForm D filed Sep 30, 2010
SEC file no. 021-148367 · accession 0001125594-10-000004 · filing 1 of 2 in this offering
Raise progress$379,026 sold of $607,341 offered (62%) · $228,315 remaining · first sale Sep 20, 2010
Issuer's note: Total offering amount includes interest on convertible promissory notes through October 29, 2010, which is the anticipated outside date for closing. Interest continues to accrue on notes until converted at closing.
Filing timingDate of first sale: Sep 20, 2010 · Form D filed: Sep 30, 2010 (10 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale5,879 days (16.1 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Oct 12, 2010 (EDGAR ↗).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors7 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$0 as filed (no minimum reported)
Securities offeredEquity
Entity detailsOrganized in PENNSYLVANIA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byThomas Petzinger Jr., CEO (Sep 30, 2010)
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Jun 15, 2010 D/A Biotechnology — $926,720 sold of $1,150,000 · 11 investors EDGAR ↗
FilingForm D/A (amendment) filed Jun 15, 2010 · amends 0001125594-10-000002 ↗
SEC file no. 021-39199 · accession 0001125594-10-000003 · filing 5 of 5 in this offering
Raise progress$926,720 sold of $1,150,000 offered (81%) · $223,280 remaining · first sale Jun 9, 2009
Filing timingDate of first sale: Jun 9, 2009 · Original Form D filed: May 28, 2009 (12 days before first sale) · This amendment (Form D/A) filed: Jun 15, 2010
This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn.
Time since first sale6,347 days (17.4 years)
Annual amendmentsIssuer reported the offering may last more than one year. This filing is an amendment dated Jun 15, 2010. Most recent amendment for this offering in our index: this filing, Jun 15, 2010.
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors11 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$0 as filed (no minimum reported)
Securities offeredDebt; Option, warrant or other right to acquire; Security to be acquired upon exercise
Entity detailsOrganized in PENNSYLVANIA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byThomas Petzinger Jr., CEO (Jun 14, 2010)
Changes vs previous filing
  • total sold: $776,720 (Jan 6, 2010) → $926,720 (Jun 15, 2010)
  • remaining: $373,280 (Jan 6, 2010) → $223,280 (Jun 15, 2010)
  • investors: 8 (Jan 6, 2010) → 11 (Jun 15, 2010)
  • may last more than one year: no (Jan 6, 2010) → yes (Jun 15, 2010)
Compared with the D/A filed Jan 6, 2010 (EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn.
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Jan 6, 2010 D/A Biotechnology — $776,720 sold of $1,150,000 · 8 investors EDGAR ↗
FilingForm D/A (amendment) filed Jan 6, 2010 · amends 0001125594-09-000003 ↗
SEC file no. 021-39199 · accession 0001125594-10-000002 · filing 4 of 5 in this offering
Raise progress$776,720 sold of $1,150,000 offered (68%) · $373,280 remaining · first sale Jun 9, 2009
Filing timingDate of first sale: Jun 9, 2009 · Original Form D filed: May 28, 2009 (12 days before first sale) · This amendment (Form D/A) filed: Jan 6, 2010
This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn.
Time since first sale6,347 days (17.4 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. This filing is an amendment dated Jan 6, 2010. Most recent amendment for this offering in our index: Jun 15, 2010 (EDGAR ↗).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors8 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$0 as filed (no minimum reported)
Securities offeredDebt; Option, warrant or other right to acquire; Security to be acquired upon exercise
Entity detailsOrganized in PENNSYLVANIA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byThomas Petzinger Jr., CEO (Jan 6, 2010)
Changes vs previous filing
  • total sold: $1,021,293 (Jan 6, 2010) → $776,720 (Jan 6, 2010)
  • total offering: $1,021,293 (Jan 6, 2010) → $1,150,000 (Jan 6, 2010)
  • remaining: $0 (Jan 6, 2010) → $373,280 (Jan 6, 2010)
  • investors: 2 (Jan 6, 2010) → 8 (Jan 6, 2010)
  • minimum investment: $333,436 (Jan 6, 2010) → $0 as filed (no minimum reported) (Jan 6, 2010)
  • date of first sale: Dec 18, 2009 (Jan 6, 2010) → Jun 9, 2009 (Jan 6, 2010)
  • securities offered: Equity (Jan 6, 2010) → Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise (Jan 6, 2010)
Compared with the D/A filed Jan 6, 2010 (EDGAR ↗). The issuer's form cites 0001125594-09-000003 as the filing it amends; the comparison here is with the filing immediately before this one in the same offering. Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn.
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Jan 6, 2010 D/A Biotechnology — $1,021,293 sold of $1,021,293 · 2 investors EDGAR ↗
FilingForm D/A (amendment) filed Jan 6, 2010 · amends 0001125594-09-000004 ↗
SEC file no. 021-39199 · accession 0001125594-10-000001 · filing 3 of 5 in this offering
Raise progress$1,021,293 sold of $1,021,293 offered (100%) · $0 remaining · first sale Dec 18, 2009
Filing timingDate of first sale: Dec 18, 2009 · Original Form D filed: May 28, 2009 (204 days before first sale) · This amendment (Form D/A) filed: Jan 6, 2010
This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn.
Time since first sale6,155 days (16.9 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. This filing is an amendment dated Jan 6, 2010. Most recent amendment for this offering in our index: Jun 15, 2010 (EDGAR ↗).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors2 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$333,436
Securities offeredEquity · business combination transaction
Entity detailsOrganized in PENNSYLVANIA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byThomas Petzinger Jr., CEO (Jan 6, 2010)
Changes vs previous filing
  • total sold: $229,720 (Dec 31, 2009) → $1,021,293 (Jan 6, 2010)
  • total offering: $229,720 (Dec 31, 2009) → $1,021,293 (Jan 6, 2010)
  • minimum investment: $75,000 (Dec 31, 2009) → $333,436 (Jan 6, 2010)
Compared with the D filed Dec 31, 2009 (EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn.
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Dec 31, 2009 D Biotechnology — $229,720 sold of $229,720 · 2 investors EDGAR ↗
FilingForm D filed Dec 31, 2009
SEC file no. 021-39199 · accession 0001125594-09-000004 · filing 2 of 5 in this offering
Raise progress$229,720 sold of $229,720 offered (100%) · $0 remaining · first sale Dec 18, 2009
Filing timingDate of first sale: Dec 18, 2009 · Form D filed: Dec 31, 2009 (13 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale6,155 days (16.9 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Jun 15, 2010 (EDGAR ↗).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors2 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$75,000
Securities offeredEquity · business combination transaction
Entity detailsOrganized in PENNSYLVANIA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byThomas Petzinger Jr., CEO (Dec 31, 2009)
Changes vs previous filing
  • total sold: $0 (May 28, 2009) → $229,720 (Dec 31, 2009)
  • total offering: $1,150,000 (May 28, 2009) → $229,720 (Dec 31, 2009)
  • remaining: $1,150,000 (May 28, 2009) → $0 (Dec 31, 2009)
  • investors: 0 (May 28, 2009) → 2 (Dec 31, 2009)
  • minimum investment: $0 as filed (no minimum reported) (May 28, 2009) → $75,000 (Dec 31, 2009)
  • date of first sale: Yet to occur (May 28, 2009) → Dec 18, 2009 (Dec 31, 2009)
  • securities offered: Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise (May 28, 2009) → Equity (Dec 31, 2009)
Compared with the D filed May 28, 2009 (EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn.
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
May 28, 2009 D Biotechnology — $0 sold of $1,150,000 · 0 investors EDGAR ↗
FilingForm D filed May 28, 2009
SEC file no. 021-39199 · accession 0001125594-09-000003 · filing 1 of 5 in this offering
Raise progress$0 sold of $1,150,000 offered (0%) · $1,150,000 remaining
Filing timingDate of first sale: Yet to occur · Form D filed: May 28, 2009
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Annual amendmentsIssuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Jun 15, 2010 (EDGAR ↗).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors0 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$0 as filed (no minimum reported)
Securities offeredDebt; Option, warrant or other right to acquire; Security to be acquired upon exercise
Entity detailsOrganized in PENNSYLVANIA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byThomas Petzinger Jr., CEO (May 28, 2009)
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Amendment history — 4 amendments on this page, each compared with the filing before it in the same offering
Amendment filedFile no.Compared withWhat changed (both values as filed)
Oct 12, 2010 EDGAR ↗021-148367Sep 30, 2010 Dtotal sold: $379,026 (Sep 30, 2010) → $493,697 (Oct 12, 2010) · remaining: $228,315 (Sep 30, 2010) → $113,644 (Oct 12, 2010) · investors: 7 (Sep 30, 2010) → 8 (Oct 12, 2010)
Jun 15, 2010 EDGAR ↗021-39199Jan 6, 2010 D/Atotal sold: $776,720 (Jan 6, 2010) → $926,720 (Jun 15, 2010) · remaining: $373,280 (Jan 6, 2010) → $223,280 (Jun 15, 2010) · investors: 8 (Jan 6, 2010) → 11 (Jun 15, 2010) · and 1 more (open the filing above)
Jan 6, 2010 EDGAR ↗021-39199Jan 6, 2010 D/Atotal sold: $1,021,293 (Jan 6, 2010) → $776,720 (Jan 6, 2010) · total offering: $1,021,293 (Jan 6, 2010) → $1,150,000 (Jan 6, 2010) · remaining: $0 (Jan 6, 2010) → $373,280 (Jan 6, 2010) · and 4 more (open the filing above)
Jan 6, 2010 EDGAR ↗021-39199Dec 31, 2009 Dtotal sold: $229,720 (Dec 31, 2009) → $1,021,293 (Jan 6, 2010) · total offering: $229,720 (Dec 31, 2009) → $1,021,293 (Jan 6, 2010) · minimum investment: $75,000 (Dec 31, 2009) → $333,436 (Jan 6, 2010)

Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Values as filed; no conclusion is drawn.

All Form D filings for this CIK on SEC EDGAR ↗. History: 0 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Jan 28, 2014. Industry as reported, by offering: All 5 offerings reported: Biotechnology (2009–2014).

Key people 8

Officers, directors and promoters the issuer itself named on its Form D. Tap a name for every other deal they are on.

NameRelationshipAddress stateOn filings (first → last)Also listed on
AV Adam W. Verost
also filed as Adam Verost
DirectorNYApr 24, 2012 → Jan 28, 2014
on 2 of 10 filings
listed on the latest filing
—
BC Barbara A. CarryerDirectorPAJan 28, 2014
on 1 of 10 filings
listed on the latest filing
—
GH Gregory T. Hebrank
also filed as Gregory Hebrank
DirectorPAMay 28, 2009 → Jan 28, 2014
on 10 of 10 filings
listed on the latest filing
5 other issuers
MT Michael A. Turpin
also filed as Michael Turpin
DirectorCTMay 28, 2009 → Jan 28, 2014
on 10 of 10 filings
listed on the latest filing
—
RU Robert UnkovicDirectorPAMay 28, 2009 → Jan 28, 2014
on 10 of 10 filings
listed on the latest filing
—
TP Thomas PetzingerExecutive Officer, DirectorPAMay 28, 2009 → Jan 28, 2014
on 10 of 10 filings
listed on the latest filing
5 other issuers
WM William MitchellDirectorPAMay 28, 2009 → Jan 28, 2014
on 10 of 10 filings
listed on the latest filing
2 other issuers
BC Barbara B. CarryerExecutive Officer, DirectorPAMay 28, 2009 → Apr 24, 2012
on 9 of 10 filings
not listed on the latest filing (Jan 28, 2014)
—

Executive officers, directors and promoters as self-reported by the issuer, one row per person. Spellings of the same name (same first and last name, or the same full name that EDGAR split differently into middle and last name) with no conflicting middle initial are shown on one row (none on this issuer); dates and counts come from the filings that list each name. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗. Middle names: the SEC Form D data set (RELATEDPERSONS.tsv) repeats the previous person's middle name into later rows of the same filing; where that happened PartnerFacts shows the name without the repeated middle name and keeps the data-set spelling on record (Adam T. Verost; Gregory B. Hebrank; Michael B. Turpin; Michael T. Turpin; Robert B. Unkovic; Robert A. Unkovic; William B. Mitchell; William T. Mitchell; William A. Mitchell) — the filing on EDGAR is the source.

Connections

Other issuers listing the same people:

Shared address: this business address appears on filings for 13 other issuers. Stated as a count only (suite numbers ignored) — many addresses are shared office buildings or registered agents. As of Oct 23, 2026, 5:45 PM ET.

Address of record is shared by 14 issuers in SEC Form D filings (shared office, PartnerFacts count as of Oct 23, 2026, 5:45 PM ET) — not used to group this issuer.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Adviser registration (Form ADV)

Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched LAUNCHCYTE LLC.

Meta advertising

No Meta Pixel ids or Facebook / Instagram page links on file for LAUNCHCYTE LLC as of Oct 24, 2026 — the sponsor website is read for them once it is on file (runs automatically). Meta Ad Library: not searched by PartnerFacts (no API access); a one-tap Ad Library search is under Look further.

Public profiles

Public profiles official links and public statements, each with its source and date

No website or social profile named in LAUNCHCYTE LLC's SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #321,319 of 374,652 in line (1,386 issuers searched so far).

Sources searched for a website: Form C data set (issuer websites as filed), Form ADV data set (Item 1.I of matched advisers) — as of Oct 23, 2026, 11:20 PM ET: none on file for this issuer. The sponsor website, the Internet Archive and GDELT news index are read only once a site is on file; a sponsor's website comes from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim, Form ADV Item 1.I of its matched adviser, or a web search for the issuer name confirmed on the site's own homepage. We never collect personal or family accounts.

Entity standing: not checked (no official programmatic source for PA yet).

Export this report as PDF (all source links + data timestamp) · Premium

Request diligence pack (Premium) PartnerFacts asks the sponsor for the standard information pack and delivers it to you labelled "provided by the sponsor".

Corrections log

No corrections have been requested for this page.

Filing-to-filing changes are in Amendment history above.

Facts from public records only, each linked to its source. No ratings, no opinions. Request a correction · Claim this profile · Facts policy

Email me the full report

The complete public-record profile for LAUNCHCYTE LLC, plus the weekly new-filings list.

What do you want to do?

Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.

Request a correction

Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).

Sponsor response

Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.

Claim this profile (sponsors)

Free. Get the "Claimed by sponsor" chip and a confirmed contact for corrections. Claiming never changes the public-record section.

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Pittsburgh, PA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn companies ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗Pennsylvania UJS portal case search ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

Pennsylvania Secretary of State business search ↗OpenCorporates ↗